Drugs / [14C]-DK-AH 269 CL
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02264028 Comparator | Mar → Apr 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [14C]-DK-AH 269 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02264028 ↗ |
| Route | Intravenous | “5 mg [14C]-DK-AH 269 CL intravenously and 10 mg [14C]-DK-AH 269 CL as oral solution” NCT02264028 ↗ |
| Route | Oral | “5 mg [14C]-DK-AH 269 CL intravenously and 10 mg [14C]-DK-AH 269 CL as oral solution” NCT02264028 ↗ |